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Chapter 1
Abnormalities of Vascular System
1
 Arterial remodelling is a major risk factor for a variety of age-related dis-
eases and represents a potential target for therapeutic development. During ageing, 
the structural, mechanical and functional changes of arteries predispose individu-
als to the development of diseases related to vascular abnormalities in vital organs 
such as the brain, heart, eye and kidney. For example, aortic stiffness increases 
nonlinearly with advancing age – a few percent prior to 50 years of age but over 
70% after 70 years of age. The elevated stiffness in large elastic arteries leads to in-
creased transmission of high pressure to downstream smaller blood vessels, in turn 
affecting the microcirculation and end-organ functions. Meanwhile, the augmented 
remodelling of small arteries accelerates central arterial stiffening. This chapter 
is to provide an overview of age-associated changes in the arterial wall and their 
contributions to both central and peripheral vascular abnormalities associated with 
ageing. Therapeutics that specially target the different aspects of arterial remodel-
ling are expected to be more effective than the traditional medications, particularly 
for the treatment and management of vascular ageing-related diseases.
Abstract
1. Introduction
 Based on their structure, location and function, arteries are distinguished by three classes 
- large elastic or conduit arteries, medium sized muscular or distributing arteries, and arterioles 
or small arteries [1]. The elastic arterial system includes aortic root, coronary arteries, common 
carotid arteries, brachiocephalic arteries, subclavian arteries, axillary arteries, brachial arter-
ies, thoracic aorta, abdominal aorta, common iliac arteries, femoral arterials, popliteal arteries 
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and tibial arteries. Elastic arteries are characterized by a large lumen and relatively thin wall 
of the blood vessels, which expand as blood pumping from the heart and recoil when the heart 
relaxes to force blood onward between beats. The muscular arteries are the numerous branches 
originated from the elastic trunks. The walls of these arteries are thick, making up over one-
fourth of the cross-sectional diameter. The arterioles are small arteries with a diameter around 
100 to 400 μm, primarily controlling the peripheral resistance and the blood flow to the capil-
lary bed [2].
 The vascular wall of all arteries consists of three tissue layers, referred to as tunics (from 
the Latin term tunica) (Figure 1). The tunica intima is lined with a single layer of flattened, 
polygonal endothelial cells that are resting on basal lamina and loose connective tissues, re-
ferred to as the sub-endothelial layer. The tunica media is the thickest layer consisting of elas-
tic laminae, each ~2-3 μm thick and spaced 5-20 μm apart. Thin layers of connective tissue 
and smooth muscle cells are arranged circumferentially within the space. The internal elastic 
lamina is a fenestrated sheet of elastin forming a boundary between the tunica media and the 
tunica intima. A second fenestrated membrane formed at the junction of the tunica media 
and the tunica adventitia is called the external elastic lamina. The number and distribution of 
elastic fibers correlate with the calibre of the artery [3]. The medial layer of muscular arteries 
occupies a larger portion of the cross sectional area than that of elastic arteries. Conversely, 
the elastic medial layer tends to exhibit a lower circumferential modulus than muscular medial 
layer. The tunica externa or adventitia contains bundles of collagen and a few elastic fibers lon-
gitudinally arranged around the vessel wall. Fibroblasts, mast cells and some smooth muscle 
cells are also present in the tunica adventitia. Arterioles differ from large arteries in the thick-
ness of the vascular wall, which consists of endothelium, a fenestrated internal elastic lamina, 
and one or two layers of smooth muscle cells, lacking the sub-endothelial layer. The internal 
elastic membrane disappears in terminal arterioles [4,5].
 
 
Figure 1: From the most interior to the outer layer, the arterial wall is composed of tunica intima, tunica me-
dia and tunica externa layers.The vessel wall of elastic artery is characterised by layers of elastic fibers in the 
tunica media and tunica externa, where as that of muscular artery contains mainly smooth muscle cells with 
less elastic fibers. The tunica media of small artery consists only one layer of elastic lamina and smooth muscle 
cells.
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 Arterioles contain oxygenated blood and control the flow into the capillary beds via 
vasodilation and constriction, which are regulated by neuronal and hormonal signals as well 
as the surrounding tissue environment [6]. The smooth muscle cell contraction significantly 
reduces the vessel lumen of arterioles. Changes in the internal diameter of arterioles regulate 
vascular resistance, arterial blood pressure and heart rate [7]. Due to the peripheral resistance, 
up to 50% of the left ventricular stroke volume is stored during systole in aorta and proximal 
large arteries and discharges during diastole [8]. The elastic properties of the large arteries help 
to reduce the fluctuation in pulse pressure over the cardiac cycle and assist in the maintenance 
of organ perfusion when cardiac ejection ceases, known as the “Windkessel effect” [8]. The 
elastic arteries become less compliant with age, resulting in a diminished Windkessel effect, 
an increased pulse pressure and elevated systolic blood pressure, which predicts the develop-
ment of cardiovascular diseases, including myocardial infarction, stroke and heart failure. The 
present chapter discusses the macroscopic and microscopic changes in the structure and func-
tion of arterial wall [i.e. remodelling] during vascular ageing. In addition, potential therapeutic 
strategies targeting arterial wall remodelling will be highlighted for important clinical applica-
tions.
2. Vascular remodelling
 Here, vascular remodelling refers to any structural and functional changes in the blood 
vessel wall. In response to local mechanical, hemodynamic and neurohumoral stimulations, 
the arterial wall is continually remodelled, as reflected at the tissue level by modifications in 
luminal diameter, wall thickness, medial and/or adventitial cross-sectional areas [9]. The pat-
tern of vascular remodelling reflects the summation of many short term vasomotor events. For 
example, in conduit arteries, chronic changes in blood flow cause alterations in the architecture 
of the blood vessel wall in order to normalize the shear stress [10]. Increases in blood flow are 
associated with an increase in lumen diameter (outward remodelling), where as decreases in 
flow are associated with a decrease in lumen diameter (inward remodelling) [11]. Apart from 
the shear stress created by blood flow, the hoop stress induced by transmural pressure promotes 
the thickening of the arterial wall in the circumferential direction [12-15]. By considering 
changes in wall cross-sectional area, the type of remodelling can be defined as hypertrophic, 
eutrophic or hypotrophic, when the cross-sectional area is increased, unchanged, or decreased, 
respectively [16]. In resistance arteries, a chronic increase in blood flow induces hypertrophic 
outward remodelling, characterized by increases in luminal diameter and cross-sectional area, 
in association with improved capacity of the endothelium to induce vasodilatation [17]. Re-
duced blood flow results in inward hypotrophic remodelling, accompanied by hyporeactivity 
of the arterial smooth muscle cells [16-18]. 
 Endothelial cells plays an important role in arterial remodelling by sensing the shear 
or frictional force between the blood flow and the vascular endothelium, in turn releasing 
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vasoactive autacoids such as nitric oxide (NO), endothelium-derived hyperpolarizing signals, 
prostaglandins and growth factors, to regulate the ability of arteries to alter their architectures 
[19,20]. Mechanical forces elicited by the flow of blood (shear stress) and pressure (cyclic 
strain) change gene expression in endothelial cells and activate endothelial nitric oxide syn-
thase (eNOS), which produces NO to regulate arterial remodelling. Removal of the endothe-
lium limits the ability of blood vessel to remodel [21]. The tunica media of the arterial vas-
culature is characterized by the prominent presence of smooth muscle cells, which execute 
the vasodilatory and vasoconstrictive functions [22,23]. Upon stimulation by mitogens [e.g. 
platelet-derived growth factor, transforming growth factor beta (TGFβ) and vascular endothe-
lial growth factor], the normally quiescent smooth muscle cells are activated to become hyper-
plasia, which contributes to the development of arterial stiffness [24-28]. Endothelium-derived 
NO inhibits growth factor-stimulated proliferation and migration of vascular smooth muscle 
cells [29]. Endothelial dysfunction is a hallmark of vascular ageing [30]. In old arteries, the 
ability of endothelium to promote vasodilatation is significantly reduced [30,31]. This reduc-
tion could be due to the reduced eNOS expression, NO bioavailability in the vessel and also 
the reduce amount of soluble guanylyl cyclase presence in aging vascular smooth muscle cells 
[32,33]. Apart from ageing, classic cardiovascular factors such as arterial hypertension, hyper-
cholesterolemia, diabetes and smoking are all associated with endothelial dysfunction [34].
 The structural components of the arterial wall consist primarily of elastin, collagen (type 
I and III) proteoglycans and glycoproteins of the extracellular matrix, which determine the 
mechanical properties such as the elasticity, tensile stiffness and compressibility [3,35-37]. 
Elastin confers compliance to the wall, allowing the artery to recoil and dampen pulsatile pres-
sure waves, whereas collagen serves to resist the distension of arterial wall at increased blood 
pressures [38]. The wall stress is born by elastin at low pressure and collagen fibers at high 
pressure, whereas the latter provides tensile strength and prevents over-distension [39,40]. 
Collagens are 100-1000 times stiffer than elastin [41]. Accordingly, arteries become stiffer as 
they distend, by a factor of 100 between mean pressures of 60 and 180 mmHg [42]. Elastin 
matures in early life and is the dominant extracellular matrix protein deposited in the arterial 
wall, contributing up to 50% of its dry weight [43]. It confers resilience and extensibility of the 
arteries. Elastic fibers stretch as vessel grow and create both longitudinal and circumferential 
tensions to smoothen stress distribution across the arterial wall [44,45]. Arteries proximal to 
the heart contain higher proportions of elastin and lower number of smooth muscle cells per 
unit volume than those of the peripheral conduit and distal muscular arteries [46]. Thus, the 
carotid, iliac and femoral arteries are stiffer than aorta [47-49]. Both circumferentially and 
longitudinally oriented elastin fibers are distributed throughout the medial layer in proximal 
elastic arteries (such as the thoracic aorta), whereas muscular arteries contain mainly longitu-
dinal elastin located within the external elastic lamina [50,51].
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 Collagen and elastin deposition are regulated by matrix metalloproteinases (MMPs) 
[52]. NO regulates the latency of MMPs to control the matrix composition of the blood ves-
sel wall, in particular collagen and elastin [53-55]. With age or under pathological conditions, 
the balance between proteases and their inhibitors is lost, as a result of increased MMP gene 
expression, the activation of zymogens or the secretion of enzymes by infiltrated inflammatory 
cells [56,57]. In aorta, collagen type I represents ~80-85% of the total collagen content and is 
organized in thick bundles to confer the rigidity and tensile strength of the vessel wall, whereas 
~5-10% collagen type III forms small fibers to promote vascular elasticity. Thus, the ratio of 
collagen type I and III determines the tensile resistance of the artery [35,58,59].
 Smooth muscle cells synthesize and maintain a balanced distribution of elastic and col-
lagen fibers in the arterial wall [35,58]. Increase in pressure stretches the arterial wall, leading 
to changes in the contractile state and/or the synthetic activity of smooth muscle cells [10].
In conduit arteries, the relatively small portions of smooth muscle cells cause only a modest 
reduction in lumen diameter, even when maximally contracted [60]. They anchor to the sur-
rounding extracellular proteins via extensions of the cytoskeleton and transmit the contracting 
muscle tension to the arterial wall [61]. Smooth muscle contraction redistributes tensile force 
between elastin and collagen,in turn modulating the arterial stiffness [61]. However, the na-
ture of connections between smooth muscle cells and the matrix molecules is not fully under-
stood. Elastin synthesis and smooth muscle cell proliferation are tightly correlated during the 
development of intimal thickening [62,63]. In summary, arterial remodelling is complex and 
dynamic process involving not only the changes of wall material and structure, but also the 
interactions between endothelium and vascular smooth muscle in response to flow-mediated 
shear stress and blood pressure-induced hoop stress.
3. Age-associated arterial remodelling
 Ageing is associated with significant alterations in structure and function of the arterial 
wall, such as the decreased production of vasodilators and increased synthesis of vasoconstric-
tors [20], augmented collagen deposition and fragmentation of elastin fibrils [3], hypertro-
phy and hyperplasia of vascular smooth muscle cells [64,65], which collectively contribute to 
thealterations in blood pressure. With age, systolic blood pressure rises continuously, whereas 
the diastolic blood pressure increases until the age of 50 and declines after the age of 55 [66, 
67]. Accordingly, the difference between systolic and diastolic pressure (pulse pressure) pro-
gressively enlarges and accelerates in later years due mainly to stiffening of the large arteries 
[67-69]. The elevation of mean arterial blood pressure reflects an increased vascular resistance 
combined with a well-preserved cardiac output [70]. Hemodynamically, increased pulse pres-
sure results from a loss of compliance in large conduit arteries and augmented wave reflections 
from the periphery. The following sections describe the age-induced structural, mechanical 
and functional changes in the three types of arteries that influence the global hemodynamic 
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regulation in a coordinative manner.
3.1 Elastic arteries
 Age-induced structural, mechanical and geometrical changes, such as thickening, stiff-
ening, dilation and elongation, limit the buffering capacities of large elastic arteries [71-74]. 
Between the age of 20 and 90 years in healthy individuals, the intima-medial layer of carotid 
arteries thickens nearly three-fold [75,76]. In the absence of observable vascular diseases, 
proliferation and migration of smooth muscle cells cause the intima of the conduit arteries to 
thicken [77]. The remodelling process restores the homeostatic responses to changes in the 
blood flow and circumferential stretch, thus maintaining a normal shear stress and wall ten-
sion [78]. Theoretically, wall thickening compensates for the rise in blood pressure. However, 
during aging or hypertension, the mechanism become ‘maladaptive’ and the wall stress sig-
nificantly increases to stimulate adverse vascular remodelling in the large elastic arteries [79].
Impaired endothelial function leads to increased resting vascular smooth muscle tone, i.e.the 
wall tension, and further deteriorates the process of arterial remodelling [60].
 The most commonly used approach for determining central arterial stiffness in humans 
is aortic or carotid-femoral pulse wave velocity (PWV), which measures the time delay and the 
distance travelled by a pulse [80]. Increased aortic stiffness, indexed as an increased PWV, is 
an independent risk factor for cardiovascular events [66,69]. During aging, the elastin content 
in large arteries remains stable, but the relative ratio of elastin to collagen decreases [81,82]. 
Fatigue fracture of the elastin fibers occurs in the proximal aorta where these fibers are most 
prominent. In the abdominal aorta, which is made up of a much larger proportion of collagen 
and smooth muscle fibers, stiffening is caused by localized calcium deposition [83-88].In ad-
dition, the accumulation of less distensible collagen fibers contributes to the progressive arte-
rial stiffness with age [60,89,90]. Increased cross-linking of collagen and localised collagen 
fibrosis contribute to the higher wall stiffness and elastic modulus in old arteries [3,91-93]. 
The expressions of both collagen type I and III are downregulated in large arteries with age, 
whereas that of collagen type VIII increases to promote smooth muscle cell migration and pro-
liferation [41]. Changes in smooth muscle cell stiffness also contribute to the global increase 
in aortic stiffening with ageing [94]. However, Angiotensin II, the principal effector of renin-
angiotensin-aldosterone system (RAAS) increases smooth muscle cell stiffness [95]. The ma-
terial stiffness of the aged artery (also known as arteriosclerosis) causes significant mechanical 
alterations, such as reduced compliance and increased impedance [96]. With age, the greatest 
decrease in distensibility and increase in PWV occur in proximal regions, when compared 
to those of the remote segments of aorta [68,97]. An increase in age of 10 years decreases 
distensibility by 30% in carotid arteries [98]. Due to variations in structure and quantity of 
the extracellular matrix components, femoral arteries exhibit differences in compliance when 
compared to carotid arteries [99]. With age, a pressure-dependent response contributes to the 
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stiffening of carotid artery, whereas a pressure-independent, intrinsic compositional change 
stiffens the wall of femoral artery [100]. The elevated stiffness in large elastic arteries leads to 
increased transmission of high pressures to downstream smaller blood vessels, in turn affect-
ing the microcirculation and end-organ functions [101-104].
 Large elastic arteries not only change the mechanical properties, but also increase the 
diameter, length and tortuosity with age [105]. The balance between the mechanical and geo-
metrical properties of the arteries progressively breaks down during ageing [73]. Advanced 
age is associated with a significant dilation or enlargement of central elastic arteries [74]. The 
aortic root dilates by over six percent between the fourth and eighth decades [74,87,104,106].
The diameter of the thoracic aorta increases by decade until age 50, flattens at 50-80 years of 
age and increases again after age 80 [107]. Proximal arteries, typically those containing more 
elastin, increase the diameter faster than distal arteries with less elastin [44]. The dilation 
may help to offset the wall stiffening by maintaining the capacity to store volume during sys-
tole. The length of the ascending aorta increases significantly with age (12% per decade) and 
correlates with the augmentation of central arterial stiffness, even in adults without apparent 
cardiovascular diseases [74]. The enlargement and elongation of large elastic arteries is more 
likely due to the degradation and fragmentation of elastin fibers and elastic laminae, which re-
leases the arterial wall stress [108]. The failure of elastic fibers to sustain physiological hemo-
dynamic stress is an indication of material fatigue and mechanical ageing in the arterial wall. 
As a result, the arterial tortuosity of both proximal and distal segments of the aorta increases 
continuously over one’s lifespan, leading to asymmetric blood flow [44]. Elastic arteries that 
contain more smooth muscle cells and less elastin show minimal age-induced mechanical and 
geometrical changes [44]. Nevertheless, compared to the central conduit vessels near the heart, 
the peripheral elastic arteries have little impact on the elastic reservoir function, pulse pressure 
and cardiac preload.
3.2 Muscular arteries
 Muscular arteries, such as the common femoral artery and the internal carotid artery, con-
tain primarily longitudinal elastic lamina located near the media/adventitia boundary, whereas 
smooth muscle cells dominate in the media [46,109]. They are more compliant longitudinally 
than circumferentially. Different from the central elastic arteries, normal aging does not cause 
enlargement in distal muscular arteries [87,110]. Age-induced remodelling is predominantly 
longitudinal and the arteries become more tortuous rather than increasing in diameter [111, 
112]. The stiffness and wall thickness of muscular arteries remain unchanged during aging 
[87,98,113]. With age, the axial force and stress decreases whereas the circumferential stress 
remains constant [111]. Degradation and fragmentation of elastin and proliferation of smooth 
muscle cells result in decreased axial pre-stretch of ageing human femoropopliteal arteries 
[111]. In contrast to the modest change in mechanical properties, endothelial function of mus-
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cular arteries, assessed as flow-mediated dilation (FMD) in the brachial artery, deteriorates 
substantially with age [114-116].
 In human pulmonary arteries, the extensibility and compliance decrease with increasing 
age. However, the medial collagen contents of the vessels exhibit a steady fall at about one 
percent per decade [117]. Ageing is accompanied by an increase in thickness and a decrease 
in the cellularity of the tunica media [27]. The content of elastin (relative to the dry weight 
of the vessel) appears to increase with age, due probably to the decrease in cellularity [118, 
119]. Nevertheless, the reduction of the arterial wall compliance is more likely due to the age-
related molecular changes in the medial elastic fibers. Fracture of elastins is associated with 
smooth muscle cell trans-differentiation leading to osteogenesis and deposition of calcium in 
the arterial wall [120-123]. Calcification is frequently encountered in aged muscular arteries 
and significantly affect the wall properties [124]. Calcium deposition is found in both intima 
and media of the vessel wall [124-127]. Calcification of the tunica media in coronary arteries 
independently predicts cardiovascular morbidity and mortality [128].
 In muscular arteries, smooth muscle cells dominate the tunica media [85]. With age, 
the intima is thickened and contains layers of smooth muscle cells [129,130]. The increased 
intima-to-media ratio is a strong predictor of future cardiovascular events [96,131-133]. In-
timal hyperplasia is primarily due to the proliferation and migration of smooth muscle cells 
from the media/adventitia to the sub-endothelial layer with additional deposition of significant 
quantities of extracellular matrix proteins [134]. During this process, vascular smooth muscle 
cells undergo phenotypic changes from “contractile” to “synthetic” in turn altering the vessel 
wall structure and mechanics [132,135]. Cyclic strain acts as a signal to stimulate the growth 
and activation of smooth muscle cells [136,137,138]. With age, endothelial dysfunction occurs 
when the balances between pro- and anti-oxidants, vasodilators and vasoconstrictors, pro- and 
anti-inflammatory molecules, and pro- and anti-thrombotic signals are perturbed [139,140]. 
Thus, although the structure of the peripheral muscular arteries is only minimally affected by 
aging, impaired vasomotor function associated with endothelial dysfunction contribute to pe-
ripheral resistance [138,141].
3.3 Small arteries
 Small arteries account for more than 40% of total peripheral resistance [142,143]. They 
have relatively high amount of smooth muscle cells that produce myogenic tone [144]. Myo-
genic contraction occurs spontaneously in response to enhanced stretch without the stimulation 
by specific vasoactive mediators. It is mediated in part by tensile strain of integrins attached 
to the extracellular matrix, which are highly sensitive to ambient calcium levels [145-147]. 
The proximal resistance arteries are the main site for vasoconstriction, which partially pro-
tects the distal resistance arteries from pressure overload [143]. However, prolonged elevation 
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of the myogenic tone stimulates vessel wall remodelling, which restores the wall stress and 
tone while increasing vascular resistance [148,149]. Proximal small arteries that exhibit less 
myogenic tone undergo outward hypertrophic remodelling [150-153]. The smaller arterioles, 
which mount a more rigorous myogenic response, exhibit inward eutrophic remodelling (a 
narrower lumen with no change in smooth muscle mass) [154]. Both hypertrophic and eu-
trophic remodelling increases the ratio of the media cross-sectional area to lumen area [155]. 
Because of incompressibility of the wall mass, a given change in tone and circumferential 
shortening elicits an enhanced effect on lumen diameter of the small arteries [156]. According 
to Poiseuille’s law (flow is related to the fourth power of the vessel radius), slight alteration in 
lumen of arteries results in significant changes in arterial resistance [87,157]. The increased 
wall-to-lumen ratio of small resistance arteries, especially the inward eutrophic remodelling, 
has the greatest value for predicting life-threatening cardiovascular events [158-161]. Assess-
ment of wall-to-lumen ratio of retinal arterioles represents an attractive tool to identify patients 
with increased cerebrovascular risk [161]. 
 With age, the stiffness of the wall components is progressively increasing [162], whereas 
the distensibility of small resistance arteries increases or remains the same [151]. The disten-
sibility is preserved in ageing arteries by geometric adaptation of the arterial wall [162]. The 
altered structure and function of small arteries exacerbate central arterial stiffness [163-166].
Mechanical strain and pulsatile stretching promote vascular smooth muscle cell migration, 
hypertrophy or hyperplasia, and matrix synthesis, resulting in a remodeled vascular wall [167-
170]. Integrins, the cell-surface adhesion receptors, mediate the crosstalk between vascular 
smooth muscle cells and the extracellular matrix environment [171]. Specific integrin receptor 
subtypes form complexes with fibronectin, and to a lesser extent collagen, to regulate cytoskel-
etal dynamics and maintain vascular myogenic force at a given pressure [172,173]. Changes 
in integrin expression profile are associated with the remodelling of both the arterial wall and 
extracellular matrix [18,174,175]. In particular, the transformation of cytoskeletal protein ac-
tin, from globular to filamentous, results in smooth muscle cell stiffening [176,177].
 Myogenic constriction plays a key role in the steady-state control of regional blood flow 
[159,178]. With advancing age, the marked increase of PWV in central large arteries together 
with a lack of stiffening in peripheral muscular arteries promote the transmission of potentially 
deleterious pulsatile energy into the peripheral microcirculation [156]. Long-term elevation 
of pulse pressure promotes the remodelling of small resistance arteries. Inward remodelling 
limits hyperemic flow reserve of the microcirculation and causes focal tissue ischemia [70, 
166,179-181]. Age-associated cardiovascular diseases in brain and kidney are characterized 
by impaired regulation of local blood flow and microscopic tissue damages [156]. In kidney, 
the glomerular capillaries are particularly vulnerable to pulsatile damages [182]. Myogenic 
response of the afferent arteriole protects the glomerulus against elevated systolic pressures 
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[183]. Impaired renal autoregulation results in an elevated glomerular capillary pressure and 
accelerated decline in kidney function [184]. Brain atrophy is correlated with cardiovascular 
risk factors and microvascular abnormalities [185]. Cerebral micro-bleeds are highly related to 
the alterations in pulse pressure [186]. High local flow facilitates penetration of excessive pul-
satile energy into the microvascular bed, contributing to repeated episodes of microvascular 
ischemia and tissue damage [187]. In brain, small vessels within the regions with white matter 
lesions exhibit thickened media and reduced internal diameter, thus a markedly increased me-
dia-to-lumen ratio [159]. Silent cortical and subcortical infarcts contribute to the development 
of age-related cognitive decline and dementia [188-193]. Importantly, chronic kidney disease, 
microvascular brain damage and cognitive impairment are frequently clustered together, sup-
porting a shared mechanism of pathogenesis [194-196].
4. Therapeutics targeting arterial remodelling 
 Cardiovascular diseases account for ~50% and ~25% of deaths in the developed and de-
veloping countries, respectively, making it the number one cause of total mortality worldwide 
[197]. In 2010, the leading risk factors and diseases accounting for global deaths and disabil-
ity-adjusted life years are hypertension (~18 and 7%), ischemic heart disease (~14 and 5%), 
tobacco smoking (~12 and 6%) and cerebrovascular disease (~11 and 4%), all of which are 
related to vascular abnormalities [34]. Therapies targeting common risk factors for cardiovas-
cular diseases, such as hypertension and dyslipidemia, are effective in reducing the total mor-
tality. For example, aggressively lowering blood pressure to below 120 mmHg significantly 
decreases all-cause mortality in patients with increased cardiovascular risks [198]. However, 
relatively few therapeutics are available for specifically modulating the arterial wall, changes 
in which play a key role in the progression of many cardiovascular metabolic and renal com-
plications.
4.1 Arterial stiffness
 Arterial stiffening has been regarded as an “inevitable” consequence of ageing [131, 
199]. In humans, femoral PWV increases by ~5.4% for each decade of life, whereas aortic 
PWV changes two-fold faster with age [200, 201]. A ~3% increase in PWV is expected to 
alter pulse pressure by ~5 mmHg and substantially alters cardiovascular risk [202,203]. Arte-
rial stiffness falls into two categories: passive and active [80]. For the former, disruption and 
fatigue fracture of the elastic fibers result in the transfer of pressure stress to collagens, leading 
to age-related arterial stiffening. The elastic modulus is commonly used to describe the proper-
ties of the wall materials such as collagen and elastin. On the other hand, arterial stiffness is de-
termined not only by the elastic modulus but also by the dimensions of the blood vessel, such 
as wall thickness [204]. Apart from the structural components, vascular endothelium plays an 
important role in the functional regulation of arterial stiffness [205]. Changes in endothelial 
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function and smooth muscle tone influence the stiffness of the elastic and muscular arteries 
[36]. Vasoconstrictors such as noradrenaline, endothelin-1 or angiotensin II increase large ar-
tery stiffness [201, 206], whereas vasodilators such as glyceryl trinitrate elicits opposite effects 
[201, 207-209].
 Central arterial stiffness is a powerful and an independent predictor of total mortality 
among older individuals [210-212], in patients with end-stage renal failure [213,214], among 
hypertensive individuals and in subjects with type 2 diabetes [215-218]. Aortic stiffness causes 
hypertension, whereas the latter aggravates this degenerative process [219-222]. Traditional 
antihypertensive agents, such as thiazide diuretics, β-blockers and calcium channel blockers 
indirectly reduce arterial stiffness by lowering mean arterial pressure, rather than having a di-
rect effect on the large arteries [223]. However, a concomitant reduction in diastolic pressure 
have adverse clinical consequences because of the reduced perfusion in coronary arteries [224].
Nitrates primarily relax smooth muscle cells in large conduit muscular arteries thus attenuat-
ing arterialstiffness and remodelling [225]. Infusion of BQ-123, an endothelin antagonist,via 
a catheter results in a significant decrease in PWV and increase in arterial distensibility. Pros-
tacyclin, apart from acting as a vasodilator, elicits anti-remodelling actions and attenuates 
smooth muscle cell proliferation. In ONgoing Telmisartan Alone and in combination with 
Ramipril Global Endpoint Trial (ONTARGET), the largest angiotensin receptor blocker car-
diovascular outcome study, both telmisartan (an angiotensin II receptor blocker) and ramipril 
(an angiotensin-converting enzyme inhibitor) prevent cardiovascular events largely by restor-
ing the endothelial functions and decreasing arterial stiffness in normotensive patients [226-
230]. The β-blocker nebivolol improves endothelial function by acting as a NO donor [231]. 
Arterial stiffness may be modified by therapies that reduce inflammation, such as hydroxy-3-
methylglutarylcoenzyme A reductase inhibitors (statins) [232,233]. Combined treatment with 
vitamins C and E improves endothelium-dependent vasodilation and arterial stiffness in un-
treated, essential hypertensive patients [234]. The advanced glycation end-products (AGE) 
accumulate in the arterial wall slowly with age and at an advanced rate in diabetic patients 
[235,236]. AGE increase the stiffness of collagen fibers by forming protein-protein crosslinks 
and preventing enzymatic digestion [237]. Non-enzymatic breaking of AGE crosslinks im-
proves arterial compliance and reduce pulse pressure in the elderly [236,238]. Despite these 
progresses, currently there lacks effective therapies that specifically target the structural and/
or mechanical components in large arteries.
4.2 Smooth muscle cell proliferation
 With age, vascular smooth muscle cells undergo functional changes to alter the normal 
structure of the arterial wall, predisposing it to the formation of neointima, atheroma and aneu-
rysm [239-241]. From the second decade of life, intimal thickening develops as an adaptive re-
sponse to luminal pressure and shear stress on the arterial wall [4,81-83]. Neointima comprises 
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layers of smooth muscle cells separated by thin elastic and collagen fibers. It exhibits con-
centric development in the aorta and eccentric appearance in the coronary arteries [242, 243]. 
Intimal thickening represents a pre-atherosclerotic lesion [85]. Small plasma-like deposits of 
glycosaminoglycans are present within the thickened intima [84]. Sub-endothelial deposition 
of cholesterol and phospholipids promotes the development of advanced atherosclerotic le-
sions [4]. While intimal hyperplasia during restenosis leads to luminal narrowing, the outward 
remodelling during atherosclerosis compensates for the plaque growth and postpones the pro-
gression to flow-limiting stenosis [244,245]. In the affected area of aneurysm, smooth muscle 
cells are switched from the contractile to a metabolic state, thus affecting the catabolism of 
elastic fibers and collagens [246]. Changes of the internal elastic lamina, including irregular 
thickness, focal absence, splitting, reduplication and calcifications, facilitate smooth muscle 
cell proliferation and migration [247]. In addition, endothelial dysfunction and lesions, as well 
as inflammatory cell recruitment and infiltration play an important role in smooth muscle call 
activation [248-250]. 
 Angiotensin II is not only a potent vasoconstrictor but also a pro-inflammatory molecule 
stimulating cell growth and matrix deposition during arterial remodelling [251]. It initiates ar-
terial remodelling via inducing smooth muscle hypertrophy, hyperplasia and migration [252]. 
The developing neointima expresses high levels of angiotensin-converting enzyme [253]. 
Blockers of angiotensin II receptor inhibit neointimal formation and reduces restenosis [254-
256]. However, large clinical trials do not support similar effects of angiotensin-converting en-
zyme inhibitors on neointimal formation and restenosis [257-259]. Smooth muscle cell activa-
tion is associated with the loss of elastic fibers in the arterial wall. Passive elastin degradation 
occurs with age, as a result of disorganization and fracture associated with the total number of 
cardiac cycles throughout life [260]. The enzymatic degradation of elastins involves MMPs-
activation [261]. Elastase decreases elastin content whereas collagenases modulate collagen 
composition. High serum MMP levels are associated with increased arterial stiffness [261]. 
Reversing the alterations to elastic fibers by targeting the proteolytic enzymes has been inves-
tigated as a therapeutic treatment for arterial ageing [260-264]. Theoretically, a combination 
of therapies is needed to inhibit the degradation and promote the proper assembly of elastic 
fibers. However, the quantification and calculation of arterial stiffness are often difficult in hu-
man, thus hindering this approach for therapeutic development.
4.3 Arterial calcification
 The incidence of aortic calcification increases steadily with age, affecting ~4% in the 
third decade of life and almost all subjects by the age of 50. Echocardiography is able to 
detect arterial calcification in approximately 30% of subjects over the age of 60 [131]. The 
fragmented elastin serves as a nidus for calcium deposition. Arterial calcification is not only a 
degenerative process during ageing, but also actively involved in the pathogenesis pathways 
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of atherosclerosis, diabetes and renal failure [126]. Calcification of the ascending aorta and 
its arch reduces their elasticity and affects the hemodynamic parameters, leading to systolic 
hypertension, left ventricular myocardial hypertrophy, diastolic dysfunction and valve incom-
petence [126]. Abdominal aortic calcium deposits are closely associated with the presence of 
calcified plaques in the coronary arteries and independently predict cardiovascular morbidity 
and mortality [265]. Therefore, therapeutic strategies targeting the abdominal region of the 
aorta may be useful in slowing the process of aortic stiffening and have an impact in reducing 
overall cardiovascular risk.
 Risk factors for vascular calcification are similar to those of atherosclerosis [266]. The 
calcifying vascular cells (a subpopulation of smooth muscle cells with osteoblastic character-
istics) are present in atherosclerotic plaques and produce mineral that clusters locally as small 
lumps, histologically resembling atherosclerotic plaque [267]. Statin-based hypolipidemic 
therapy reduces the intensity of calcification of vessel walls and cardiac valves [268-273]. 
Apart from the calcification associated with atherosclerosis in the arterial intima, a more dif-
fuse deposition of calcium salts termed medial elastocalcinosis is seen in the arterial media 
of patients with diabetes or renal failure [123,274,275]. Hyperglycemia causes activation of 
vascular smooth muscle cells to differentiate into osteoblast-like cells [276]. In patient with 
chronic kidney disease, diabetes enhances arterial calcification irrespective of the stage of re-
nal insufficiency [277]. Pharmacological control of elastocalcinosis may be a new approach to 
the treatment of essential systolic hypertension [278]. Suppression of endothelin by sinitrodil, 
a NO donor, induces mineral loss in the aorta. Treatment with eplerenone, an aldosterone re-
ceptor inhibitor,inhibits calcific aortic stenosis in animal models [279,280]. The increase in 
arterial calcium deposition is related to the decreased bone mineral density in humans [121, 
122,281]. Optimal control of calcium and phosphate concentrations attenuates the progression 
of vascular lesions in patients with end-stage renal disease, for whom vessel calcification re-
mains a major problem [282,283]. Drugs used for osteoporosis treatment (calcitriol, estradiol, 
bisphosphonates) may interfere with the calcification processes occurring in the vessel wall 
[284,285]. For example, increase in arterial stiffness and calcification is associated with the 
administration of vitamin D and nicotine [286]. On the other hand, drugs used to treat cardio-
vascular problems (statins, angiotensin convertase inhibitors, warfarin, heparins) may have an 
effect on bone tissue metabolism.
4.4 Arteriolar myogenic tone
 In small resistance arteries, the activation of myogenic tone represents a major deter-
minant in the regulation of local hemodynamics [287]. The myogenic response is initiated 
when the mechanical signal induces membrane depolarization of the vascular smooth mus-
cle cells, in turn causing Ca2+ mobilization and activation of contractile proteins [288,289]. 
Thus, in response to changes in intravascular pressure, vascular smooth muscle cells, which 
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are arranged circumferentially or near perpendicular to the long axis of the vessel, become 
shortened to constrict the blood vessel [290]. Smooth muscle cell depolarization is mediated 
by the activation of cation channels, the closure of K+ or the opening of Cl- channel, which 
subsequently activate voltage-gated Ca2+ channels (VGCC) [291-295]. The molecular identity 
of the cation channel(s) leading to stretch-induced depolarization remains to be characterized 
[296]. Endothelial cells induce hyperpolarization of smooth muscle cells in small resistance 
arteries via the activation of small-conductance Ca2+-activated K+ channel (SKCa, blocked by 
apamin or UCL 1684) and intermediate-conductance Ca2+-activated K+ channel (IKCa, blocked 
by charybdotoxin or TRAM-34) [297-300]. Progressive reduction of endothelium-dependent 
hyperpolariation is observed during ageing in normotensive animals and humans [301-304]. 
 Vasodilating drugs, such as hydralazine, dipyridamole and calcium channel blockers, 
act to decrease resistance of the smaller arterioles [296], whereas adrenergic stimulation en-
hances myogenic vasoconstriction [305]. Blockage of VGCC by nifedipine or nisoldipine 
(L-type Ca2+ channel blockers) eliminates active myogenic constriction but does not affect 
mechanosensation and membrane depolarization of smooth muscle cells [306-309]. Myogenic 
responses of small arterioles less than 25 μm in diameter (such as those in skeletal muscle) 
are relatively insensitive to Ca2+ channel blockers [310]. Drugs targeting the regulation of 
myogenic constriction possess therapeutic potentials for pathologies including hypertension, 
cerebral or coronary vasospasm, and vascular complications associated with insulin resistance 
and overt diabetes [296]. Different vascular beds use distinctive intracellular mechanisms for 
myogenic tone regulation. The heterogeneity across tissues provides potential benefit for de-
signing specific therapeutic interventions of the myogenic tone [308,311-313]. For example, 
Rho-kinase inhibitors are more effective than nitroglycerin to induce vasodilatation in vasos-
pastic coronaries for patients with refractrory angina [314]. In kidney, myogenic constriction 
of afferent arterioles attenuates the transmission of high pressure to the glomerular capillar-
ies, thus preventing hyperfiltration and glomerulosclerosis [315,316]. Pharmacological agents 
modulating the specific myogenic mechanisms would confer an advantage over those with 
general activities on vascular activations [172].
5. Concluding remarks
 Vascular ageing is characterized by the structural, mechanical and functional alterations 
of the arterial wall and represents a fundamental process underlying the development of many 
ageing-related diseases. For example, an increased media-to-lumen ratio of small arteries is 
associated with an increased prevalence of cardiovascular events, whereas the augmented inti-
ma-media thickness in large arteries predicts the occurrence of both stroke and myocardial in-
farction. Arterial remodelling involves both cellular (e.g. endothelial and smooth muscle cells) 
and non-cellular components (e.g. elastins and collagens). With age, endothelial dysfunction, 
smooth muscle cell proliferation and migration, extracellular matrix synthesis or degradation 
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collectively contribute to the stiffness of central elastic arteries, which increases the systolic 
and pulse pressure, leading to microcirculatory complications in end organs such as brain, 
kidney and heart. 
 Aging-associated arterial remodelling is fundamentally intertwined with the arterial al-
terations associated with other well-known risk factors (e.g. excess food intake, altered me-
tabolism, smoking, hypertension and lack of exercise). Understanding how aging, stiffness, 
and blood pressure interact over time is a complex conundrum. Some lifestyle and pharmaco-
logical interventions have proved to be effective in preventing or ameliorating hypertension. 
However, the majority of therapeutics target the consequences rather than the pathophysiology 
of vascular ageing. For example, traditional antihypertensive therapies, including the RAAS, 
calcium channel and beta-blockers, indirectly reduce the stiffness of arteries by lowering total 
peripheral resistance but not the arterial remodelling directly associated with aging. There lacks 
effective agents that specifically modulate the mechanical properties of the arterial wall.
 Arteries exhibit differences in their microstructural organization, constituent mass ratios 
and mechanical responses depending on the anatomic locations and physiologic functions, 
which predispose them to varying mechanical responses and pathologies. Considering the 
versatile and dynamic nature of the vascular beds, the prevention of arterial ageing would re-
quire early intervention, life long treatment and site-specific approaches. The endothelium is a 
favourite early target of vascular ageing. Nevertheless, in vivo assessment of arterial structure 
and function will provide more accurate insights to define disease-free age-related changes in 
arteries and then consider the most effective therapeutic target for modulating the process of 
arterial remodelling.
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